The Record - for physicians and other health care providers to share with their office staffs Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print entire issue

July 2016

All Providers

Blue Cross to implement 2016 InterQual® criteria Aug. 1

Reminder: Home care criteria

As we told you last year, InterQual Home Health Care Criteria is only available electronically through the InterQual View application.

You can sign up for home care content within the InterQual View application at mhsinfo.mckesson.com/BCBSMIHomecare.* Organizations with multiple locations will need to sign up for access at each location.

After you sign up, you’ll receive login information and a license key to download and unlock the content with step-by-step instructions.

If you have any questions or concerns about accessing home health care criteria, contact Adair Galster, a senior client executive for McKesson, at 773-935-4605 or Adair.Galster@mckesson.com.

Blue Cross Blue Shield of Michigan will implement 2016 InterQual acute care, rehabilitation, skilled nursing, long-term acute care and home health criteria, starting Aug. 1, 2016.

The criteria format for rehabilitation, skilled nursing and long-term acute care hasn’t changed, but there were some changes made to the home health care criteria format last year. For details, see article at right.

This year, there are still 32 adult and 24 pediatric acute care criteria for specific conditions. General medical and surgical categories will remain in their previous format for patients who don’t fall within a condition-specific subset.

The acute care criteria transition plan section lists those conditions associated with a high risk of readmissions. This information can be useful in determining which patients to refer to our Case Management department.

The "Acute Care Quality Indicators" section lists the indicators for improving the quality of hospital care. The National Quality Forum developed these national standard indicators.

InterQual criteria should be applied to all elective or emergency hospital admissions.

Blue Cross modifications to InterQual criteria, also called local rules, were posted on web-DENIS in June. To access them:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications and Resources in the left column.
  • Click on Newsletters & Resources.
  • Click on Clinical Criteria & Resources.

Submitting InterQual comments

If you have questions, concerns or comments about InterQual® criteria, email McKesson Health Solutions at CESupport@mckesson.com and include the following:

  • The name and address of your facility
  • A note indicating that this is a question related to InterQual and which criteria set you’re inquiring about

Or you can email your provider consultant if you have questions. Don’t know who that is? Visit the Contact Us section of bcbsm.com/providers to locate the provider consultant for your area. Click on their name to access their email address.

Note: Our InterQual Criteria Helpline is no longer active.

To help us respond to you quickly and accurately, provide the following information when emailing your provider consultant:

  • Criteria book you're using
  • Page number from that book
  • Criteria you have a question about
  • Your question, comment or concern

Here’s an example of how to format a question:

Under “Acute Criteria, Adult” on Page ADLT-15 Acute Coronary Syndrome, INTERMEDIATE, Intervention: Do newer oral anticoagulants alone meet this criterion?

 Be sure to include your name and your organization’s name.

**Blue Cross Blue Shield of Michigan doesn’t own or control the content of this website.


Submit 2016 service dates for MA Diagnosis Closure Incentive program

Need access to Health e-Blue?

If your primary care office doesn’t have access to Health e-Blue, apply today. Visit bcbsm.com/provider and then:

  • Click on Provider Secured Services.
  • Under Solutions available through Provider Secured Services, click on Health e-Blue for Blue Care Network patient data and Blue Cross Blue Shield of Michigan Medicare Advantage patient data.
  • Complete all fields on both the Health e-Blue Application and the Use and Protection Agreement, and return them to the address on the form.

To maintain access to the system, make sure you sign in to Health e-Blue at least every six months.

Tips for signing up for Health e-Blue

  • All applications need to be completed and signed by a primary care physician or primary care physician manager.
  • The practice name has to match across the application.
  • Provide state license number (can send additional pages if you’re out of space).
  • Include any previously created web-DENIS ID to help the Health e-Blue team provide faster service. (Web-DENIS IDs usually start with a D or F.)
  • Use your full legal name on the application.

The 2016 Medicare Advantage Diagnosis Closure Incentive program is effective for dates of service Jan. 1, 2016, or later. As part of the program, health care providers should complete patient diagnoses, supported by any necessary documentation in their medical records and following M.E.A.T. (manage, evaluate, assess or treat) guidelines.

You’re required to address 2016 diagnosis gaps with a face-to-face visit with your patients by Dec. 31. You then have until Jan. 31, 2017, to submit results of your 2016 patient visits on Health e-Blue. (See article at right for information on accessing Health e-Blue.)

Your patients’ diagnosis gaps are identified on Health e-Blue’s Diagnosis Evaluation panel. Health care providers may use the monthly reports on Health e-Blue to document that diagnosis gaps have been closed.

Keep in mind that if a prior service year date is entered for a 2016 diagnosis gap, the diagnosis gap will open with the next refresh and the gap closure won’t count toward your 2017 incentive payment.

Physicians who close 100 percent of all identified gaps for each attributed patient will receive $100 per patient. Your incentive payment will be mailed to you by the end of the third quarter in 2017.

See the March Record for details.

For questions about dates of service, diagnosis gap submissions or the Diagnosis Closure Incentive program, contact Tom Rybarczyk at 313-225-0445 or Corinne Vignali at 313-225-7782. Rybarczyk and Vignali are provider consultants on the Healthcare Effectiveness Data and Information Set and risk adjustment provider outreach team.

HEDIS® is a registered trademark of the National Committee for Quality Assurance.




Here are tips for searching the provider manuals

How to find the provider manuals
In our May 2016 issue, we told you about the new Provider Manuals page that’s now available on the lower right side of the Welcome screen after logging in to your provider account at bcbsm.com. The Provider Manuals page includes a link to each of the four Blue Cross Blue Shield of Michigan and Blue Care Network provider manuals.

You can also find the new Provider Manuals page on web-DENIS in the left-hand column.

5

Have you ever been frustrated when you couldn’t find something in the Blue Cross Blue Shield of Michigan provider manuals? Here’s how to make your search easier and more productive.

If you know which provider manual chapter you want to search, first open the chapter. Then:

  • Press Ctrl + F on your keyboard. (Press F while you hold down the Ctrl key.) This will open the Find dialog box.
  • Enter a search term in the Find dialog box.
  • Click Next.

1

  • Keep clicking Next until you find what you’re looking for.

Each time you click Next, you’ll be taken to another location in the chapter where your search term appears.

The Ctrl + F method of searching can be used in any document, not just in a provider manual chapter. For instance, you can also use it on The Record Archive page to help you find a newsletter article headline.

When using Ctrl + F, the more words you use, the fewer results you’ll get. That’s because the more words that are in your search term, the fewer are the chances that all those words will appear together — and in the exact order in which you’ve arranged them — in the document you’re searching. For example, if you search for “claim” in the Claims chapter, you’ll find more than 100 results. However, if you search for “claim form,” you’ll find 13 matches.

If you don’t know which provider manual chapter you want to search, you can search the entire provider manual using the Keyword Search and the Virtual Document.

  1. Keyword search

    After selecting your Provider Type, click on Keyword(s) in the Provider Manuals dashboard.
    2
    This will open a Keyword Criteria panel that offers you two boxes in which to type keywords. You can only type one word in each of the boxes. If you type two words in one box, you will not get any results.
    w
    When you click Finish and then click Search in the dashboard, the computer will take up to a minute to compile your list of manual chapters that contain the search words you’ve chosen. In some cases, there will be many chapters in the result. This is the case for the example shown above. The search terms “claim” and “appeal” exist in 12 chapters of the MD-DO provider manual. If you don’t want to click through each chapter to find what you’re looking for, you can use the Virtual Document.
  1. Virtual Document

    The first item listed in the search results is the Virtual Document. When you click on it, you’ll get the following message in green: The requested virtual document has been created. Click the Jobs tab to view it.
    4
    When you click on the Jobs tab, you’ll see a document listed. Click on it and it will open one long document that contains every chapter that was in your Keyword search results.
  1. Use Ctrl + F

    Now you can use Ctrl + F to open the Find dialog box and click on Next to quickly review all instances of your search terms in the manual.

If you need assistance, Provider Inquiry or your provider consultant can help. You can also send an email to ProviderManuals@bcbsm.com for concerns related to the Blue Cross provider manuals.


Use Medical Record Routing Form as cover sheet when sending medical records to Blue Cross

When sending records to us, it’s important to fill out the Medical Record Routing Form and use it as your cover sheet. This applies to:

  • Medical records we’ve requested from you
  • Supporting medical records you’re sending to us as part of a request to review a rejected claim

Instructions for filling out the form online are included with it on web-DENIS. Once we receive the completed form with the records, all of the documents are scanned into our repository. Then the department responsible for reviewing the claim and documentation is notified that the records have been received.

Allow 30 days for medical record reviews.

For BlueCard® claims, the completed form and medical records should only be submitted if you received a BlueCard claim rejection requesting the records.

Below are some tips to ensure your records are reviewed promptly:

Follow these guidelines

  • Fill out the Medical Record Routing Form on web-DENIS, print it and use it as your cover sheet.
  • Fax the routing form and medical records totaling 100 pages or fewer to 1-866-617-9917.  Medical record documentation more than 100 pages should be mailed to us at the address on the bottom of the form.
  • Contact our Provider Inquiry staff if you have questions on a medical record request or to find out the status of your records review if you haven’t received a response to the claim after 30 days.

Avoid these missteps

  • Don’t attach a paper claim form to the Medical Record Routing Form with your records.
  • Don’t attach multiple records for different claims or patients to a single routing form.
  • Don’t copy the form and complete it by manually writing in the required information.

The Medical Record Routing Form can be found under the Frequently Used Forms section of web-DENIS. Follow these steps:

  1. Go to bcbsm.com.
  2. Log in as a provider.
  3. Click on web-DENIS.
  4. Click on BCBSM Provider Publications and Resources.
  5. Click on Newsletters and Resources.
  6. Click on the Frequency Used Forms section in the upper right corner of the page.
  7. Choose Medical Records Routing Form.

HCPCS codes added, deleted

The Centers for Medicare & Medicaid Services has added 12 new HCPCS codes, deleted three codes and added one modifier as part of its quarterly HCPCS updates.
The new codes are listed below.

Code

Change

Coverage comments

Effective date

Q5102

Added

Covered

July 1, 2016

Q9981

Added

Covered

July 1, 2016

Q9982

Added

Not covered

July 1, 2016

Q9983

Added

Not covered

July 1, 2016

S0285

Added

Covered

July 1, 2016

S0311

Added

Not covered

July 1, 2016

S3854

Added

Not covered

July 1, 2016

C9476

Added

Not covered

July 1, 2016

C9477

Added

Not covered

July 1, 2016

C9478

Added

Not covered

July 1, 2016

C9479

Added

Not covered

July 1, 2016

C9480

Added

Not covered

July 1, 2016

The deleted codes are listed below.

Code

Change

Effective date

C9458

Deleted

June 30, 2016

C9459

Deleted

June 30, 2016

C9743

Deleted

June 30, 2016

Following is the added modifier.

Modifier

Change

Coverage comment

Effective date

ZB

Added

Informational only

July 1, 2016



For UAW retirees, report condition dates on ER professional claims to comply with new policy

We’d like to clarify a policy that took effect Jan. 1 for members of our UAW Retiree Medical Benefits Trust. URMBT members must receive emergency room services within 72 hours of the onset of the condition for which they are seeking treatment. If they receive services after 72 hours, we won’t cover those services.

This applies to professional and facility claims.

To ensure your claim is processed correctly, begin reporting the patient’s condition date on the ER professional claim. Failure to report the condition date could result in delays or a rejected claim. The condition code date is also required on the hospital’s emergency room claim.
1

If you have any questions on a rejected claim, contact our Provider Inquiry department for assistance.


Look for online updates to our prescription drug lists

Blue Cross Blue Shield of Michigan recently updated its online prescription drug lists, or formularies.

We regularly update these lists to help ensure patient safety and assist prescribers in selecting the most effective and affordable drug therapy for their patients.

You can view the most recent prescription drug list updates, including updates to the custom select drug list, at bcbsm.com/rxinfo. You can also see other pharmacy-related information at this link.

Our prescription drug lists can help prescribers make better-informed prescribing decisions that can lead to increased medication adherence. They can also help health care providers explain prescription drug coverage to our members.


BlueCard® connection: Why does my claim on web-DENIS have a 17-digit number in the ICN field?

Blue Cross Blue Shield of Michigan uses a 14-digit internal control number to identify all commercial claims in our system, including ones for the BlueCard® program.

But you may see a “710” code at the end of the 14-digit ICN when viewing a claim on web-DENIS on the Claims Summary page. The numbers “710” represent our Michigan plan code.

Our plan code should never be included when you’re asked to report an ICN on a replacement or void claim, or when completing the Medical Records Routing Form.

For more information on the BlueCard program, including links and articles on online tools, reference the BlueCard chapter of the online provider manuals.

If you’re experiencing issues with the information provided in the BlueCard chapter of the online manual — or if you’d like more information on a particular topic — contact your provider consultant.

Want to suggest a topic to be covered in this series? Send an email to ProvComm@bcbsm.com and put “BlueCard series” in the subject line.


Coding corner: Proper coding for major depressive disorder

Possible symptoms of an MDD episode

  • Depressed or irritable mood
  • Decreased interest or pleasure
  • Change in activity
  • Fatigue or loss of energy
  • Diminished concentration
  • Guilt or sense of worthlessness
  • Significant change in weight or appetite
  • Change in sleep patterns
  • Thoughts of death, self-harm or suicide

Major depressive disorder is also known as clinical, unipolar or recurrent depression. It’s defined as a mood disorder having a clinical course involving one or more episodes of serious psychological depression lasting two or more weeks per episode with no intervening episodes of mania.

You should always document the symptoms of MDD in the patient’s medical record to substantiate the diagnosis. Be sure to provide details of the most recent episode the patient experienced.

According to the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), at least five of the nine symptoms listed at right need to be present on a regular basis during the same two-week period for the patient to be diagnosed with MDD. At least one of the symptoms must either be a depressed mood or loss of interest.

MDD is assigned to ICD-10 subcategories, depending on whether the condition is a single episode (F32.–) or a recurrent episode (F33.–). A fourth character is always necessary when coding MDD. The fourth-digit subclassifications specify the severity of the condition and identify the presence of related psychotic features, if applicable. A fifth character is only necessary when using subcategory F33.4– (major depressive disorder, recurrent, in remission) to specify if the patient is in partial, complete or an unspecified level of remission.

The terms utilized for the fourth- and fifth-digit subclassifications of MDD are used in conjunction with the specific diagnostic criteria listed below. The list details the level of severity along with the requirements needed to diagnose the severity.

  • Unspecified: This term is used when the information in the medical record is insufficient to assign a more specific code.
  • Mild: The patient experiences at least five of the symptoms needed for a diagnosis of MDD, which also pose a mild overall functional impairment.
  • Moderate: The patient experiences seven to eight symptoms, or the symptoms he or she suffers from pose a moderate overall functional impairment.
  • Severe without psychotic features: The patient experiences most or all of the symptoms, or the symptoms he or she experiences pose a severe functional impairment, but the patient presents without any psychotic features.
  • Severe with psychotic features: The patient experiences most or all of the symptoms, or the symptoms he or she experiences pose a severe functional impairment and the patient presents with psychotic features.
  • In full remission: The patient previously had two or more episodes but has been free from symptoms for at least two months.
  • In partial remission: Some symptoms may still be present but the full criteria are no longer met, or there are no longer any significant symptoms of an episode, but the patient hasn’t been in remission for two months or longer.

Caution should be taken when coding to a specific severity level without that level being stated in the medical record, even if documentation of the clinical requirements for that level of severity are noted in the medical record. Providers should clearly state the level of severity of the depression and correlate this with supporting documentation, such as current prescribed medications, a PHQ-9 or another standardized assessment.

The major difference between ICD-9 and ICD-10 coding for depression is that medical record documentation that simply states “depression” and has no further supporting documentation will now index to “major depression, single episode, unspecified (F32.9).” Following are all the code choices for MDD.

ICD-10 code choices

  • F32.0: MDD, single episode, mild
  • F32.1: MDD, single episode, moderate
  • F32.2: MDD, single episode, severe without psychotic features
  • F32.3: MDD, single episode, severe with psychotic features
  • F32.4: MDD, single episode, in partial remission
  • F32.5: MDD, single episode, in full remission
  • F32.9: MDD, single episode, unspecified
  • F33.0: MDD, recurrent episode, mild
  • F33.1: MDD, recurrent episode, moderate
  • F33.2: MDD, recurrent episode, severe without psychotic features
  • F33.3: MDD, recurrent episode, severe with psychotic features
  • F33.40: MDD, recurrent episode, in remission, unspecified
  • F33.41: MDD, recurrent episode, in partial remission
  • F33.42: MDD, recurrent episode, in full remission
  • F33.9: MDD, recurrent episode, unspecified

 None of the information included herein is intended to be legal advice and as such it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

J3490

Basic benefit and medical policy

BRIDION® (sugammadex) is covered for its FDA-approved indications

Effective Dec. 15, 2015, BRIDION® (sugammadex) is covered for its FDA-approved indications for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.

Report with HCPCS code J3490.

J3490

Basic benefit and medical policy

OTIPRIO™ (ciprofloxacin) is covered for FDA-approved indications

Effective Dec. 10, 2015, OTIPRIO™ (ciprofloxacin) is covered for FDA-approved indications. OTIPRIO (ciprofloxacin) should be reported with code J3490 until a permanent code is established. Pharmacy doesn’t require preauthorization of this drug.

J7199

Basic benefit and medical policy

Idelvion factor IX recombinant

Effective March 16, 2016, Idelvion factor IX recombinant (albumin fusion protein) is covered for FDA-approved indications. Idelvion coagulation factor IX recombinant (albumin fusion protein) should be reported with code J7199 until a permanent code is established. Pharmacy doesn’t require preauthorization for this drug.

31295, 31296, 31297

Basic benefit and medical policy

Catheter-based inflatable device for treatment of chronic sinusitis

The safety and effectiveness of the use of a catheter-based inflatable device (balloon ostial dilation) for the treatment of chronic sinusitis have been established, effective March 1, 2016. It may be considered a useful therapeutic option when indicated.

Basic benefit policy group variations
This change doesn’t apply to Michigan Public School Employees Retirement System members.

Inclusions

  • Documentation of chronic rhinosinusitis greater than three months
  • Documented failure of medical therapy greater than three months demonstrated by persistent upper respiratory symptoms despite treatment consisting of all the following:
    • Minimum of two different antibiotics
    • Trial of steroid nasal spray
    • Trial of antihistamine nasal spray or decongestant
  • Radiological evidence, in the sinus to be dilated, of at least one of the following:
    • Air fluid levels
    • Mucosal thickening
    • Opacification
    • Nasal polyposis

Exclusions

  • Ciliary dysfunction
  • Cystic fibrosis
  • Sinonasal tumors or obstructive lesions
  • Severe/gross polypoid disease
  • Adolescent or child with incomplete bony development

Balloon sinus ostial dilation used as an adjunct during functional endoscopic sinus surgery, or FESS, is considered integral to the primary FESS procedure and not separately reimbursable.

27279, 27280

Basic benefit and medical policy

Minimally invasive sacroiliac joint fusion

The safety and effectiveness of minimally invasive sacroiliac joint fusion have been established. It may be considered a useful therapeutic option when supporting documentation substantiates appropriate patient selection criteria listed under inclusions and exclusions. This policy is effective March 1, 2016.

Basic benefit policy group variations
MPSERS members are excluded from this change.

Inclusions
This procedure is indicated for the treatment of sacroiliac joint pain for patients with low back/buttock pain who meet all of the following criteria:

  • Additional or alternative diagnoses that could be responsible for the patient’s ongoing pain or disability have been ruled out (e.g., L5/S1 compression, hip osteoarthritis, tumors).
  • Failure to respond to at least six months of non-surgical treatment consisting of non-steroidal anti-inflammatory drugs or opioids (if not contraindicated) and one or more of the following: rest, physical therapy, SIJ steroid injection. Failure to respond means continued pain that interferes with activities of daily living or results in functional disability.
  • SIJ pain confirmed with at least three physical examination maneuvers that stress the SIJ and cause the patient’s typical pain.
  • Controlled sacroiliac joint blocks, using local anesthetic agents of different duration of action for controlled comparison with or without placebo, are recommended to confirm the diagnosis when clinical findings are consistent with disabling sacroiliac joint pain.
  • Achieving 75 percent or greater pain relief, with the ability to perform previously painful movements after injection is considered a positive response.

Exclusions
This procedure isn’t indicated in the presence of:

  • Less than six months of pain
  • Failure to pursue conservative treatment
  • Systemic arthropathy such as ankylosing spondylitis or rheumatoid arthritis
  • Generalized pain behavior (e.g., somatoform disorder) or generalized pain disorder (e.g., fibromyalgia)
  • Infection, tumor or fracture
  • Neural compression as seen on MRI or CT that correlates with the patient’s symptoms or other more likely source for their pain

0042T

Basic benefit and medical policy

Computed tomography-based perfusion imaging

Computed tomography-based perfusion imaging may be considered established to select patients with stroke for mechanical embolectomy, effective May 1, 2016.
CT-based perfusion imaging of the brain is considered experimental for all other indications. It hasn’t been scientifically demonstrated to improve patient clinical outcomes.

Payment policy
This procedure is excluded from the radiology management program and doesn’t require preauthorization.

Inclusions
CT-based perfusion imaging to select patients with stroke for mechanical embolectomy.

Exclusions
CT-based perfusion imaging of the brain for all other indications not specified under the inclusions.

UPDATES TO PAYABLE PROCEDURES

S9977

Basic benefit and medical policy

Meal allowance, non-patient companion meals will no longer be covered
 
The IRS determined that the cost of meals that aren’t a part of inpatient care can’t be included in medical expenses. If Blue Cross Blue Shield of Michigan continues to cover them, it must report these payments to the IRS for each subscriber. As a result, Blue Cross determined that it can no longer provide the meal allowance and the non-patient companion meals will no longer be covered.

43644, 43645, 43770- 43775, 43842, 43843, 43845- 43848, 43886- 43888,
43999**, 44130, 96101- 96103, S2083

**Used for open sleeve gastrectomy

Non-covered: 43999***

*** When used to indicate any of the following procedures:

  • Loop gastric bypass gastroplasty, also known as mini-gastric bypass
  • Stomach stapling
Endoscopic procedures to treat weight gain after bariatric surgery

Basic benefit and medical policy

Laparoscopic, open gastric restrictive procedures
The safety and effectiveness of laparoscopic and open gastric restrictive procedures, including gastric-band, Roux-en-Y, gastric bypass, sleeve gastrectomy and biliopancreatic diversion, have been established. They may be considered useful therapeutic options when specified criteria are met.

Exclusionary criteria have been updated, effective July 1, 2016.

Inclusions
The surgical procedures for severe obesity, including sleeve gastrectomy, are considered established treatment options if all the following criteria are met:

  • The patient has a BMI greater than 40 or a BMI of greater than 35 with one or more co-morbid conditions including:
    • Degenerative joint disease (including degenerative disc disease)
    • Hypertension
    • Hyperlipidemia, coronary artery disease
    • Presence of other atherosclerotic diseases
    • Type II diabetes mellitus
    • Sleep apnea
    • Congestive heart failure
  • Bariatric surgery may be indicated for patients 18 to 60 years old. Requests for bariatric surgery for patients younger than 18 should include documentation that the primary care doctor has addressed the risk of surgery on future growth, the patient's maturity level and the patient’s ability to understand the procedure and comply with postoperative instructions, as well as the adequacy of family support. Patients older than 60 may be considered if it’s documented in the medical record that the patient’s physiologic age and co-morbid conditions result in a positive risk-to-benefit ratio.
  • The patient has been clinically evaluated by an M.D. or D.O. (or their authorized delegate [e.g., physician assistant, etc.]).  The physician has documented failure of non-surgical management including a structured, professionally supervised (physician or non-physician) weight-loss program for a minimum of:
    • Six full, consecutive months (180 days) within the last four years before the recommendation for bariatric surgery (for Blue Cross patients. Or six full, consecutive months (180 days) within the last two years before the recommendation for bariatric surgery (for Blue Care Network patients).
    • The six full, consecutive month (180 days) weight-loss program listed above is waived for super morbidly obese individuals who have a BMI equal to or greater than 50. Documentation should include periodic weights, dietary therapy and physical exercise, as well as behavioral therapy, counseling and pharmacotherapy, as indicated.
  • Documentation that the primary care doctor and the patient have a good understanding of the risks involved and reasonable expectations that the patient will be compliant with all post-surgical requirements.
  • A psychological evaluation must be performed as a pre-surgical assessment by a contracted mental health professional to establish the patient’s emotional stability, ability to comprehend the risk of surgery and to give informed consent, and ability to cope with expected postsurgical lifestyle changes and limitations. Such psychological consultations may include one unit total of psychological testing for purposes of personality assessment (e.g., the MMPI-2 or adolescent version, the MMPI-A).
  • The physician needs to be aware and follow up with individuals who have had gastric surgery for any long-term complications.
  • In cases where a revision of the original procedure is planned because of failure due to anatomic or technical reasons (e.g., obstruction, staple dehiscence, etc.), or excessive weight loss of 20 percent or more below ideal body weight, the revision is determined to be medically appropriate without consideration of the initial preoperative criteria. The medical records should include documentation of:
    • The date and type of the previous procedure
    • The factors that precipitated the failure or the nature of the complications from the previous procedure that mandate (necessitate) the takedown
  • If the indication for the revision is a weight gain or a failure of the patient to lose a desired amount of weight due to patient non-adherence, then the patient must qualify for the subsequent procedure and meet all of the initial preoperative criteria.

Exclusions
The following surgical procedures are considered experimental because their safety or effectiveness has not been proven:

  • Gastric bypass using a Billroth II type of anastomosis, also known as mini gastric bypass
  • Biliopancreatic bypass without duodenal switch
  • Long-limb gastric bypass procedure (i.e., greater than 150 centimeters)
  • Stomach stapling
  • Endoscopic or endoluminal procedures (including insertion of the StomaphyX™ device, insertion of a gastric balloon, endoscopic gastroplasty or use of an endoscopically placed duodenojejunal sleeve) as a primary bariatric procedure or as a revision procedure, (e.g., to treat weight gain after bariatric surgery to remedy large gastric stoma or large gastric pouches)
  • Any bariatric surgery for patients with Type 2 diabetes who have a BMI of less than 35
  • Laparoscopic gastric plication
  • Vagus nerve blocking (see separate policy, “Vagus Nerve Blocking for Morbid Obesity”)
  • Single anastomosis duodeno-ileal bypass with sleeve gastrectomy

77301, 77338, 77385, 77386, 77387, G6015, G6016

Basic benefit and medical policy

Intensity-modulated radiotherapy

Intensity-modulated radiotherapy, or IMRT, may be considered established for the treatment of localized prostate cancer and after radical prostatectomy when specified criteria are met.

The medical policy statement and criteria have been updated, effective July 1, 2016.

Inclusions
Localized prostate cancer

  • 75.6 to 79.2 Gy in conventional fractions for patients with low-risk cancers. Low-risk features in localized prostate cancer are defined as stage T1-T2a, Gleason score of 6 or less and prostate-specific antigen, or PSA, level less than 10 ng/mL
  • 81.0 Gy for patients with intermediate- and high-risk cancers:
    • Intermediate risk: Stage T2b-T2c or Gleason score 7 or PSA levels between 10 and 20
    • High risk: Stage T3a or Gleason score of 8 to 10 or PSA level greater than 20 ng/mL based post-prostatectomy
  • Adjuvant therapy when there are adverse pathologic findings at prostatectomy or with a persistently detectable PSA level post-prostatectomy.
  • Salvage therapy when there is evidence of biochemical or local recurrence when there’s no evidence of distant metastatic disease.

Exclusions
All other situations not specified under the inclusions.

90867, 90868, 90869

Basic benefit and medical policy

Transcranial magnetic stimulation of the brain

Transcranial magnetic stimulation of the brain has been established. It may be a useful treatment option in specified situations.

Inclusionary criteria have been updated, effective July 1, 2016.

Inclusions
Note: Transcranial magnetic stimulation must be administered by an approved U.S. Food and Drug Administration cleared device for the treatment of major depressive disorder, or MDD, according to specified stimulation parameters, five days a week for six weeks (total of 30 sessions), followed by a three-week taper of three transcranial magnetic stimulation treatments in one week, two transcranial magnetic stimulation treatments the next week and one transcranial magnetic stimulation treatment in the last week.

Must meet all of the following:

  • The member is 18 to 70 years old.
  • A urine drug screen is obtained if indicated by current clinical, history or a high degree of clinical suspicion.
  • Has a confirmed diagnosis of severe major depressive disorder (single or recurrent episodes) without psychosis measured by evidence-based scales such as Beck Depression Inventory (score 30-63), Zung Self-Rating Depression Scale (>70), PHQ-9 (>20) or Hamilton Depression Rating Scale (>20)
  • At least one of the following:
    • Medication treatment resistance during the current depressive episode evidenced by  each of the following:
      • Lack of a clinically significant response to four trials of psychopharmacologic agents. Trial criteria is six weeks of maximal FDA recommended dosing or maximal tolerated dose of medication with objectively measured evaluation at initiation and during the trial showing no evidence of response (i.e., less than 50 percent reduction of symptoms or scale improvement). At least two trials should be
      • Two single agent trials of antidepressants of different classes
      • Two augmentation agent trials with different classes of augmenting agents using either or both of the agents in the above single agent trials
      • The patient is unable to tolerate a therapeutic dose of medications.  Intolerance is defined as severe somatic or psychological symptoms that can’t be modulated by any means, including additional medications to ameliorate side effects. Examples of somatic side effects include persistent electrolyte imbalance, pancytopenia, severe weight loss, poorly controlled metabolic syndrome or diabetes, as a result of the medication. Examples of psychological side effects of the medication would be suicidal-homicidal thinking or attempts, impulse dyscontrol.

        Note: A trial of less than one week of a specific medication wouldn’t be considered a qualifying trial to establish intolerance.
    • Electroconvulsive therapy wouldn’t be clinically superior to transcranial magnetic stimulation (e.g., in cases with psychosis, acute suicidal risk, catatonia or life-threatening inanition rTMS should not be utilized)
  • A trial of an evidence-based psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms  (e.g., Becks Depression Inventory, Zung Self-Rating Depression Scale, PHQ-9, or Hamilton Depression Rating Scale)
  • The following conditions are continuously present in the rTMS treatment setting during treatment:
    • Treatment must be by a board-certified psychiatrist, trained in this therapy
    • An attendant trained in basic cardiac life support, or BCLS, and  the management of complications such as seizures, as well as the use of the equipment must be present at all times
    • Presence of adequate resuscitation equipment including, for example, suction and oxygen
    • The facility must maintain awareness of response times of emergency services (either fire/ambulance or code team), which should be available within five minutes. These relationships are reviewed on at least a one-year basis and include mock drills.

Requests for repeat rTMS therapy in patients who have attained remission subsequent to initial rTMS therapy and experienced relapse will be reviewed for individual consideration.

Exclusions

  • All other behavioral health, neuropsychiatric or medical conditions (e.g., anxiety disorders, mood disorders, schizophrenia, Alzheimer’s, dysphagia, seizures)
  • Pregnancy
  • Maintenance treatment
  • Presence of psychosis in the current episode
  • Seizure disorder or any history of seizure, except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence
  • Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 centimeters from the TMS magnetic coil or other implanted metal items, including a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents

Note: Dental amalgam fillings aren’t affected by the magnetic field and are acceptable for use with TMS.

  • If the patient or, when indicated, the legal guardian is unable to understand the risk and benefits of rTMS and provide informed consent
  • Presence of a medical or co-morbid psychiatric contraindication to rTMS
  • Patient lacks a suitable environmental, social or professional support system for post-treatment recovery.
  • There isn’t a reasonable expectation that the patient will be able to adhere to post-procedure recommendations.

Note: Caution should be exercised in any situation where the patient’s seizure threshold may be decreased.  Examples include:

  • Presence in the bloodstream of a variety of agents, including tricyclic antidepressants, clozapine, antivirals, theophylline, amphetamines, PCP, MDMA, alcohol and cocaine as these present a significant risk
  • Presence of the following agents, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, some antipsychotics, chloroquine, some antibiotics and some chemotherapeutic agents as they present a relative risk and should be considered when making risk-benefit assessments

Withdrawal from alcohol, benzodiazepines, barbiturates and chloral hydrate also present a strong relative hazard.

POLICY CLARIFICATIONS

64575, L8680, L8681, L8682, L8683, L8685, L8686, L8687, L8688

 Experimental/Investigational:

39599, 0424T, 0425T, 0426T, 0427T, 0428T, 0429T, 0430T, 0431T, 0432T, 0433T, 0434T, 0435T, 0436T

Basic benefit and medical policy

Phrenic nerve stimulation/diaphragm pacing

The safety and effectiveness of phrenic nerve stimulation/diaphragm pacing have been established. It may be a useful therapeutic option when indicated for selected patients, using devices that have been granted full pre-market approval from the U.S. Food and Drug Administration.

The exclusionary criteria have been updated, effective July 1, 2016.

Inclusions
Patients with ventilatory failure from stable, high spinal cord injuries or central alveolar hypoventilation syndrome when all criteria are met:

  • Bilateral clinically acceptable phrenic nerve function is demonstrated with EMG recordings and nerve conduction times
  • Individual has normal chest anatomy, a normal level of consciousness, and the individual has the ability to participate in and complete the training and rehabilitation associated with the use of the device
  • Stimulation of the diaphragm either directly or through the phrenic nerve results in sufficient muscle activity to accommodate independent breathing without the support of a ventilator

Exclusions

  • Phrenic nerve pacers with only Humanitarian Device Exemption or Investigational Device Exemption are excluded (e.g., NeuRx)
  • Chronic obstructive pulmonary disease
  • Individuals who can breathe spontaneously for four hours or more without use of a mechanical respirator
  • Individuals with intact phrenic nerve and diaphragm function
  • Individuals whose respiratory insufficiency is temporary
  • Motor neuron disease, such as amyotropic lateral sclerosis, or ALS
  • Treatment of any other condition where the phrenic nerve and diaphragm are intact (for example, chronic obstructive lung disease, central sleep apnea, restrictive lung disease, singultus, or hiccups)
  • Underlying cardiac, pulmonary, such as chronic obstructive pulmonary disease, or chest wall disease is present that is significant enough to prevent spontaneous breathing off a ventilator for more than four hours even with the use of the phrenic nerve or diaphragm pacemaker device

S8930, 97813, 97814, E1399, 97139, 63650, 64555, 99070, L8680

Basic benefit and medical policy

Cranial electrotherapy is experimental

Cranial electrotherapy (also known as cranial electrostimulation therapy, or CES) and electrical stimulation of auricular acupuncture points are experimental. These therapies haven’t been scientifically demonstrated to be as effective as conventional treatment. The policy was reviewed and updated, effective July 1, 2016.

95803

Basic benefit and medical policy

Actigraphy alone for diagnosis of sleep disorders is experimental

Actigraphy alone for the diagnosis of sleep disorders and other indications is experimental. There is insufficient scientific evidence in the current medical literature to indicate that this technology is as beneficial as the established alternatives.

(When used as a component of portable sleep monitoring, actigraphy shouldn’t be reported separately.)

This policy is effective July 1, 2016.

21120, 21121, 21122,  21123, 21141, 21196, 21198, 21199, 42140, 42145

Experimental:

41512, 41530, 42299, 64999, S2080

Basic benefit and medical policy

Obstructive sleep apnea surgical procedures

Certain surgical procedures have been established as safe and effective for the treatment of clinically significant obstructive sleep apnea, or OSA, when conservative therapies or CPAP alone has failed. The choice of the procedure should be tailored to the individual patient’s need based on anatomy and etiology.

Exclusionary criteria have been updated, effective July 1, 2016.

Inclusions

  • Uvulectomy or uvulopalatopharyngoplasty for the treatment of clinically significant** obstructive sleep apnea syndrome in adult patients who haven’t responded to or don’t tolerate continuous positive airway pressure, or CPAP
  • Hyoid suspension, surgical modification of the tongue or maxillofacial surgery, including mandibular-maxillary advancement in adult patients with clinically significant** OSA and objective documentation of hypopharyngeal obstruction who haven’t responded to or don’t tolerate CPAP
  • Adenotonsillectomy in pediatric patients with OSA and hypertrophic tonsils and one of the following:
    • AHI or respiratory disturbance index, or RDI, of at least five per hour
    • AHI or RDI of at least 1.5 per hour in a patient with excessive daytime sleepiness, behavioral problems or hyperactivity

**Clinically significant obstructive sleep apnea is defined as failure of conservative treatments for sleep apnea, such as weight loss, modification of the patient’s sleep position, medications to relieve nasal obstruction and avoidance of evening alcohol and hypnotics, use of CPAP or oral appliances and polysomnography with one of the following:

  • AHI or RDI greater than or equal to 15 events per hour
  • AHI or RDI greater than or equal to five events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease or history of stroke

Exclusions

  • Implantable hypoglossal nerve stimulators
  • Laser-assisted palatoplasty
  • Midline glossectomy
  • Palatal stiffening procedures, such as Cautery-assisted and injection snoreplasty
  • Palatal implants
  • Radiofrequency volumetric tissue reduction of the tongue
  • Radiofrequency reduction of the palatal tissues (i.e., somnoplasty)
  • Tongue base suspension (i.e., Repose system)
  • All other minimally invasive surgical procedures not described above
  • All interventions for the treatment of snoring in the absence of documented OSA

81321, 81322, 81323

Basic benefit and medical policy

Genetic testing for PTEN hamartoma tumor syndrome 

Genetic testing for a PTEN mutation is established to confirm the diagnosis when a patient displays clinical signs of a PTEN hamartoma tumor syndrome or in a first-degree relative of a proband with a known PTEN mutation. It may be considered medically necessary when indicated.

Genetic testing for a PTEN mutation is considered experimental for all other indications, including prenatal testing. This policy is effective July 1, 2016.

Inclusions

  • Genetic testing for a PTEN mutation to confirm the diagnosis of a PTEN hamartoma tumor syndrome when a patient displays clinical signs of any of the following suspected PTEN hamartoma tumor syndromes (see policy "Background/Description" section for detailed criteria):
    • Bannayan-Riley-Ruvalcaba syndrome
    • Cowden syndrome
    • PTEN-related Proteus syndrome
    • Proteus-like syndrome
  • Genetic testing for a PTEN mutation in a first-degree relative of a proband with a known PTEN mutation.

Exclusions

  • Prenatal genetic testing for a PTEN mutation
  • All other indications not listed in the inclusion section

Established: 27415, 27416, 28446
29866, 29867

Experimental: 27899, 29999

Basic benefit and medical policy

Autografts and allografts in the treatment of focal articular cartilage lesions

The criteria have been updated for the autografts and allografts in the treatment of focal articular cartilage lesions policy. This policy is effective July 1, 2016.

The safety and effectiveness of osteochondral allografting and autografting for defects of the knee have been established. It’s a useful therapeutic option for patients meeting specific patient selection criteria. 

Osteochondral allografting
The safety and effectiveness of osteochondral allografting to repair large (e.g., 10cm2) full-thickness chondral defect of the knee caused by acute or repetitive trauma have been established. It’s a useful therapeutic option for selected patients.

Osteochondral allografting for all other joints (other than the knee) is experimental. It hasn’t been shown to improve patient outcomes better than conventional treatment.

Osteochondral autografting
The safety and effectiveness of osteochondral autografting, using one or more cores of osteochondral tissue, have been established for the treatment of symptomatic full-thickness cartilage defects of the knee caused by acute or repetitive trauma in patients who have had an inadequate response to a prior surgical procedure, when the inclusionary criteria are met.

Osteochondral autografting for all other joints, including talar, and any indications other than those listed above, is considered experimental. Treatment of focal articular cartilage lesions with autologous or allogeneic minced cartilage is considered experimental.
 
Inclusions

  • For osteochondral allografting: This procedure is appropriate for patients with large full-thickness chondral defect of the knee caused by acute or repetitive trauma in patients
  • For osteochondral autografting: This procedure is appropriate for patients with full-thickness chondral defect of the knee caused by acute or repetitive trauma in patients who have had an inadequate response to a prior surgical procedure. In addition, all of the following criteria must be met:
    • Patient age:
      • Adolescent patients should be skeletally
        mature with documented closure of growth plates (e.g., 15 or older).
      • Adult patients should be too young to be considered an appropriate candidate for total knee arthroplasty or other
        reconstructive knee surgery (e.g., younger than 55 years).
    • Focal, full-thickness (grade III or IV) unipolar lesions on the weight-bearing surface of the femoral condyles, trochlea or patella that are between 1 and 2.5 cm2 in size
    • Documented minimal to absent degenerative changes in the surrounding articular cartilage (outerbridge grade II or less) and normal-appearing hyaline cartilage surrounding the border of the defect
    • Normal knee biomechanics or alignment and stability achieved concurrently with osteochondral grafting

Exclusions

  • Osteochondral allografting or autografting for all other joints, including shoulder, elbow, talar and any indications other than those listed above is considered experimental.
  • Treatment of focal articular cartilage lesions with autologous or allogenic minced cartilage

Established: 0336T

Experimental: 0404T, 58578, 58999

Basic benefit and medical policy

Myolysis of uterine fibroids using laparoscopic, percutaneous or transcervical techniques

The criteria have been updated for the myolysis of uterine fibroids using laparoscopic, percutaneous or transcervical techniques policy. This policy is effective July 1, 2016.
 
Laparoscopic ultrasound-guided radiofrequency ablation (e.g., Acessa™) for the treatment of uterine fibroids is established. It may be considered a useful therapeutic option when indicated.  

Laparoscopic and percutaneous techniques of myolysis as a treatment of uterine fibroids other than laparoscopic ultrasound-guided radiofrequency ablation (e.g., Acessa™) are considered experimental, including Nd: YAG lasers, bipolar electrodes and cryomyolysis.   There’s insufficient published evidence to assess the safety and impact on health outcomes in the treatment of uterine fibroids.

Transcervical, intrauterine ultrasound-guided radiofrequency ablation in the treatment of uterine fibroids is experimental. There’s insufficient published evidence to assess the safety and impact on health outcomes.

Inclusions
Laparoscopic ultrasound-guided radiofrequency ablation (e.g., Acessa™) for the treatment of uterine fibroids may be indicated as an alternative to hysterectomy or myomectomy when the member has one or more of the following:

  • Severe menorrhagia causing anemia
  • Bulk-related symptoms (e.g., pelvic pain, pressure or discomfort, urinary symptoms related to compression of the ureter or bladder, or dyspareunia)
  • Contraindications to general anesthesia
  • Pre-menopausal state with symptomatic fibroids in members who want to avoid a hysterectomy

Exclusions

  • Laparoscopic ultrasound-guided radiofrequency ablation (e.g., Acessa™) for all situations other than those specified above
  • Transcervical, intrauterine ultrasound-guided radiofrequency ablation in the treatment of uterine fibroids

Established: 95004, 95017, 95018, 95024, 95027, 95028, 95044, 95052, 95056, 95070, 95071, 95076, 95079

Specified immunotherapy codes: 95115, 95117, 95120, 95125, 95130, 95131, 95132, 95133, 95134, 95144, 95145, 95146, 95147, 95148, 95149, 95165, 95170, 95180

Specified laboratory codes: 82785, 86001, 86003, 86005

Experimental: 86343, 95060, 95065, 95199, 30999

Basic benefit and medical policy

Allergy testing and immunotherapy

The safety and effectiveness of selected allergy testing and immunotherapy treatment of allergies have been established. They may be considered useful diagnostic and therapeutic options when indicated. This policy is effective July 1, 2016.

Inclusions

Allergy testing:

  • Bronchial challenge tests
  • Direct skin test (percutaneous [scratch, prick or puncture] or intracutaneous [intradermal])
  • Double-blind food challenge test
  • Patch test (application test)
  • Photo patch test
  • Specific IgE in vitro tests (radioallergosorbent test, or RAST; multiple-antigen simultaneous test, or MAST; fluoro-allergosorbent testing, or FAST; enzyme-linked immunosorbent assay, or ELISA; ImmunoCAP)
  • Total serum IgE concentration
  • Serial end point titration (SET or Rinkel method) when there’s a high likelihood for a severe allergic reaction to specific agents such as antibiotics, nuts or other high-risk allergens

Immunotherapy treatments: Appropriate in patients with demonstrated allergic hypersensitivity that can’t be managed by medications or avoidance.

Note: Injections of airborne insect venom allergens should be prepared individually for each patient.

Exclusions

Allergy testing:

  • Antigen leukocyte cellular antibody, or ALCAT, automated food allergy testing (also see separate JUMP policy titled “Antigen Leukocyte Antibody Test”)
  • Applied kinesiology or Nambudripad’s allergy elimination test, or NAET (i.e., muscle strength testing or measurement after allergen ingestion)
  • Anti-Fc Epsilon receptor antibodies
  • Anti-IgE receptor antibody testing
  • Blood, urine or stool micro-nutrient assessments
  • Candidiasis test
  • Chemical analysis of body tissues (e.g., hair)
  • Chlorinated pesticides (serum)
  • Clifford materials reactivity testing
  • Complement (total or components)
  • Complement antigen testing
  • Conjunctival challenge test (ophthalmic mucous membrane test)
  • C-reactive protein
  • Cytokine and cytokine receptor assay
  • Cytotoxic food tests
  • Cytotoxic testing for environmental or clinical ecological allergy testing (Bryans test, ACT)
  • Direct nasal mucous membrane test
  • Electrodermal testing or electro-acupuncture
  • Electromagnetic sensitivity syndrome/disorder (allergy to electricity, electro-sensitivity, electrohypersensitivity and hypersensitivity to electricity)
  • Environmental cultures and chemicals
  • Eosinophil cationic protein, or ECP, test
  • Food immune complex assay, or FICA, or food allergenic extract immunotherapy
  • General  immune system assessments
  • Immune complex assay
  • Immunoglobulin G (IgG) testing for allergy
  • Iridology
  • Leukocyte antibodies testing
  • Leukocyte histamine release test (LHRT)/basophil histamine release test
  • Live cell analysis
  • Lymphocytes (B or T subsets)
  • Lymphocyte function assay
  • Mediator release test, or MRT, or the LEAP program
  • Metabolic assessments
  • Multiple chemical sensitivity syndrome (aka, idiopathic environmental intolerance, or IEI, clinical ecological illness, clinical ecology, environmental illness, chemical AIDS, environmental/chemical hypersensitivity disease, total allergy syndrome, cerebral allergy, 20th century disease)
  • Nasal challenge test
  • Passive transfer
  • Prausnitz-Kustner, or P-K testing – passive cutaneous transfer test
  • Provocative tests for food or food additive allergies
  • Pulse response test
  • Qualification of  nutritional assessments
  • Rebuck skin window test
  • Secretory IgA (saliva)
  • Sage complement antigen test
  • Specific immunoglobulin (IgG) (e.g., by RAST, seldom used or enzyme-linked immunosorbent assay)
  • Sublingual provocative neutralization testing and treatment with hormones
  • Total serum IgG, immunoglobulin A (IgA) and immunoglobulin M (IgM)
  • Venom blocking antibodies
  • Volatile chemical panels (blood testing for chemicals)

Immunotherapy:

  • Provocative and neutralization therapy for food allergies, using intradermal and subcutaneous routes
  • Rinkel, also known as serial dilution endpoint titration therapy, for ragweed pollen hay fever
  • Enzyme -potentiated desensitization, or EPD
  • Repository emulsion therapy
  • Urine auto injections (autogenous urine immunization)
  • Rhinophototherapy

Established: 17380, 19303, 19304, 19318, 19350, 54520, 55970, 55980, 56805, 57335, 58150, 58152, 58180,  58260, 58262, 58275, 58291, 58541, 58542, 58543, 58544, 58550, 58552, 58553, 58554

Experimental: 11950, 11951, 11952,  11954, 15820, 15821, 15822, 15823, 15824, 15825, 15826, 15828, 15830, 15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839, 15876, 15877, 15878, 15879, 21120, 21121, 21122, 21123, 21125, 21127, 30400, 30410  30420, 39430, 30435, 30450

Basic benefit and medical policy

Transgender services

The safety and effectiveness of selected medical and surgical treatments of gender dysphoria have been established. The established treatments of gender dysphoria include:

  • Puberty suppression in adolescents
  • Cross-sexual hormone therapy (for masculinization/feminization)
  • Medically necessary gender reassignment surgery**:
    • Genitalia reconstruction
    • Mastectomy in female-to-male transitions

(**Gender reassignment surgery may require prior authorization.)

Gender-specific services may be medically necessary for transgender people appropriate to their anatomy.  Examples include:

  • Breast cancer screening may be medically necessary for female-to-male transitioned people who haven’t undergone a mastectomy.
  • Prostate cancer screening may be medically necessary for male-to-female transitioned people who have retained their prostate.
  • Cervical screening may be medically necessary for female-to-male transitioned people, as needed. 

 This policy was effective May 1, 2016.

Puberty suppression***

Puberty suppression hormones for adolescents may be indicated for members that meet all of the following inclusionary criteria.

Inclusions

  • Onset of puberty to at least Tanner stage 2
  • The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed)
  • Gender dysphoria emerged or worsened with the onset of puberty
  • Any coexisting psychological, medical or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment
  • The adolescent has given informed consent and, particularly when the adolescent hasn’t reached the age of medical consent, the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process 
  • The absence of contraindications to therapy in the judgment of the managing physician

***Medications for puberty suppression may be managed under the member’s pharmacy benefit.

Hormone therapy****

Hormone therapy may be indicated for members who meet all of the following inclusionary criteria.

Inclusions

  • Persistent, well-documented gender dysphoria
  • Capacity to make a fully informed decision and to consent for treatments
  • Aged 18 or older (age of majority)
  • If significant medical or mental health concerns are present, they must be reasonably well-controlled
  • The absence of contraindications to therapy in the judgment of the managing physician

****Medications for hormone therapy may be managed under the member’s pharmacy benefit.

Gender reassignment surgery

Gender reassignment surgery may be indicated for members who meet all of the following inclusionary criteria.

Inclusions

  • Persistent, well-documented gender dysphoria
  • The provider must supply documentation that supports the member meets criteria for gender reassignment surgery. This includes a detailed psychological assessment by either a psychiatrist, PhD prepared clinical psychologist or a master’s prepared social worker under the supervision of a psychiatrist or PhD prepared clinical psychologist
  • Eighteen years of age or older
  • Capacity to make a fully informed decision and to consent for treatment
  • If significant medical or mental health concerns are present, they must be controlled
  • Twelve continuous months of hormone therapy*** as appropriate to the patient’s gender role (unless there is a contraindication to hormonal therapy):
    • Hormonal therapy ***is not required before mastectomy in female-to-male patients
    • The aim of hormone therapy before gonadectomy is primarily to introduce a period of reversible estrogen or testosterone suppression, before the patient undergoes irreversible surgical intervention.
  • Twelve continuous months of living in a gender role that is congruent with their gender identity.

Some patients receiving transgender services may require and benefit from ongoing behavioral health services, including psychotherapy.

Exclusions

  • Transgender services aren’t covered if contract or certificate language contains specific exclusion of these services.
  • Reversal of transgender surgical procedures.
  • All surgical procedures that are primarily cosmetic and not medically necessary, including:
    • Abdominoplasty
    • Blepharoplasty
    • Breast enhancements
    • Brow lift
    • Calf implants
    • Cheek and malar implants
    • Chin and nose implants
    • Chondrolaryngoplasty (Adam’s apple reduction)
    • Collagen injections
    • Construction of a clitoral hood
    • Drugs for hair loss or growth
    • Forehead lift
    • Hair removal
    • Hair transplantation
    • Lip reduction
    • Liposuction
    • Mastopexy
    • Neck tightening
    • Pectoral implants
    • Removal of redundant skin
    • Rhinoplasty
    • Speech language therapy
    • Non-covered services
EXPERIMENTAL PROCEDURES

31660, 31661

Basic benefit and medical policy

Bronchial thermoplasty for the treatment of asthma 

The safety and effectiveness of bronchial thermoplasty for the treatment of asthma haven’t been established. Further studies are needed to evaluate the clinical utility, safety and long-term health implications of this procedure. Bronchial thermoplasty for the treatment of asthma is experimental. This policy is effective July 1, 2016.

36511, 37799, S2107

Basic benefit and medical policy

Adoptive immunotherapy (CAR-T therapy) 

Adoptive immunotherapy (CAR-T therapy) of all applications are considered investigational. Autologous lymphocytes used as part of adoptive immunotherapy may be harvested in a pheresis procedure or may be isolated from re-sected tumor tissue. This policy is effective July 1, 2016.

81313, 81479, 0010M

Basic benefit and medical policy

Genetic and protein biomarkers for the diagnosis and cancer risk assessment of prostate cancer 

Genetic and protein biomarkers for the diagnosis and cancer risk assessment of prostate cancer are considered experimental. This includes the following:

  • Kallikrein markers (e.g., 4Kscore™ Test)
  • Metabolomic profiles (e.g., Prostarix™)
  • PCA3 testing
  • TMPRSS fusion genes
  • Candidate gene panels
  • Mitochondrial DNA mutation testing (e.g., Prostate Core Mitomics Test™)
  • Gene hypermethylation testing (e.g. ConfirmMDx®)
  • MiPS (Mi-ProstateScore)

 This policy is effective July 1, 2016

S1090, 0406T, 0407T

Basic benefit and medical policy

Implantable sinus stents for postoperative use after endoscopic sinus surgery 

The use of implantable sinus stents for postoperative treatment after endoscopic sinus surgery and for treatment of recurrent sinonasal polyposis is considered investigational. This policy is effective July 1, 2016.

GROUP BENEFIT CHANGES

American Axle

Effective July 1, 2016, American Axle is adding a segment.

Group number: 75415
Alpha prefix: AXL - PPO
Platform: NASCO

Plans offered:
Medical
Pharmacy
Hearing
American Well® (online office visits)

Sheet Metal Workers’ Local 80 Insurance Trust Fund

Effective June 1, 2016, Medicare-eligible retirees of Wayne County have Blue Cross Blue Shield of Michigan’s Medicare Advantage PPO plan, Medicare Plus BlueSM Group PPO for their medical, surgical and prescription drug benefits.

Group number: 67791
Suffixes: 600, 601, 602
Alpha prefix: XYL

Plans offered:
Medicare Advantage PPO
Medicare Plus Blue Group PPO, medical, surgical, prescription drug

For more information about our Medicare Advantage PPO plan, go to bcbsm.com/provider/ma.

Western Michigan Health Insurance Pool

Effective July 1, 2016, Western Michigan Health Insurance Pool will be adding several schools to its group:

  • Ingham ISD
  • St. Joseph ISD
  • Clinton County RESA
  • Lansing Community College
  • Ravenna Public Schools

Group number: 71565
Alpha prefix: WYO

Plans offered:
PPO
HSA
Prescription drugs


Professionals

Here’s how newborn coverage was updated

When Blue Cross Blue Shield of Michigan became a mutual company in January 2014, its newborn coverage policy changed. We want to make sure you are aware of these updates.

Newborn coverage changes

  • Newborns are covered for the first 31 days from the date of their birth whether or not the baby is listed on the subscriber’s contract. Coverage includes both well-baby care visits and claims for injury, sickness, congenital defects and birth abnormalities. If the baby is not enrolled on the subscriber’s contract on day 32, coverage under our 31-day newborn coverage policy terminates.
  • The 31-day newborn coverage policy applies to either the mother’s or the father’s contract, whoever is the subscriber. The mother is not required to be listed on the father’s contract for the newborn to be covered.
  • The 31-day newborn coverage does not apply to the newly born child of a dependent. If the mother is a dependent (not the subscriber or the spouse) on the contract, then claims for the newborn will be denied. Blue Cross does not provide coverage to the newborn of a dependent unless the subscriber has legal responsibility for the newborn. Coverage for the newborn may be available through other sources.

Note: The 31-day newborn coverage policy does not apply to Federal Employee Program® members. For self-funded groups, newborn coverage is determined by the group’s plan.

For additional information about our newborn coverage policy, refer to the benefit section of our online provider manuals, which will be updated to include information on this policy July 1, 2016.

If you have questions regarding a denied claim or to status a claim that you reported, please contact Provider Inquiry.


Blue Cross not covering select high-cost drugs with comparable alternatives

To address the high cost of drugs and provide the best value for our members, Blue Cross Blue Shield of Michigan commercial plans will no longer cover select high-cost, U.S. Food and Drug Administration-approved drugs for which more cost-effective therapeutic alternatives are available. This doesn't apply to Michigan Education Special Services Association members.

The initial drugs targeted for this initiative are Jublia®, Kerydin® and Onmel®, a group of medications used to treat onychomycosis, or toenail fungus. These drugs will no longer be covered beginning Aug. 1, 2016.

The following table includes the approximate cost of the brand-name drugs and associated therapeutic alternatives:

Brand-name drugs not covered beginning Aug. 1, 2016, and their costs**

Therapeutic alternatives and their costs**

Jublia topical solution (eficonazole)

$1,290

ciclopirox topical solution (Penlac®)

$50

Kerydin topical solution (tavaborole)

$1,614

terbinafine tablet (Lamisil®)

$390

Onmel tablet (itraconazole)

$1,164

itraconazole capsule (Sporanox®)

$557


**Approximate cost for a 30-day supply based on the average wholesale price.

In some cases, members’ out-of-pocket costs for these brand-name drugs may be lower than their copay due to manufacturer savings cards. However, the high cost of these drugs is reflected in future premium rates and may affect the claims experience for both members and plans.

As part of this ongoing initiative, Blue Cross will continue to identify select high-cost drugs and will stop covering them when there are more cost-effective alternatives available for our commercial members.


Blue Cross adding 2 additional specialty drugs to Medical Drug Prior Authorization program Oct. 1

Beginning Oct. 1, 2016, two more specialty drugs will need prior authorization from Blue Cross Blue Shield of Michigan before they’ll be covered under a member's medical benefits.

Keep in mind that prior authorization is just a clinical review approval, not a guarantee of payment. Providers will still need to verify the necessary coverage for this medical benefit. Our office will accept the medical drug prior authorization request forms, with supporting documentation, for these newly added drugs as early as Aug. 1, 2016.

Starting Oct. 1, 2016, the following two drugs will need prior authorization:

Drug name

HCPCS code

Inflectra

Q5102

Remicade®

J1745

You can find medication request forms, within the list of medications that need prior authorization, on web-DENIS:

  1. Click on BCBSM Provider Publications and Resources.
  2. Click on Commercial Pharmacy Prior Authorization and Step Therapy forms.
  3. Click on Physician administered medications (on the right side under Frequently Used Forms).

We won’t consider a request for coverage until we receive a physician-signed medication request form faxed or mailed to Blue Cross, or a request uploaded onto NovoLogix, an online-based tool. Standard processing time for request review is 15 days. An urgent request can be reviewed within 72 hours.

The list** below shows all the medications that are part of the Medical Drug Prior Authorization Program.

Actemra®

Depo®-Testosterone

Immune globulin

Prolia®

Acthar® gel

Dysport®

Kalbitor®

Ruconest®

Adagen®

Elaprase®

Kanuma™

Signifor® LAR

Aldurazyme®

Elelyso™

Krystexxa®

Simponi® Aria™

Aralast NP™

Entyvio™

Lemtrada™

Soliris®

Aveed®

Fabrazyme®

Lumizyme®

Stelara®

Benlysta®

Firazyr®

Makena®

Synagis®

Berinert®

Flebogamma® DIF

Myobloc®

Testopel®

Bivigam™

Gammagard Liquid®

Myozyme®

Tysabri®

Botox®

Gammagard® S/D

Naglazyme®

Vimizim™

Carimune® NF

Gammaked®

Nplate®

Vpriv®

Cerezyme®

Gammaplex®

Nucala®

Xeomin®

Cimzia®

Gamunex®

Octagam®

Xgeva®

Cinqair®

Glassia™

Orencia®

Xiaflex®

Cinryze®

Hizentra®

Privigen®

Xolair®

Cosentyx™

HyQvia®

Probuphine®

Zemaira®

Delatestryl®

Ilaris®

Prolastin®-C

 

Note: The prior authorization requirement doesn’t apply to Medicare, Medicare Advantage or Federal Employee Program® members.

**Blue Cross reserves the right to change this list at any time.


Confirm your provider directory information in CAQH ProView

It’s important that your contact information in the Blue Cross Blue Shield of Michigan and Blue Care Network health care provider directory is accurate, current and complete. Patients and referring physicians use this information to search for a health care practice that meets their needs.

New federal and state regulations require regularly updated, accurate information in provider directories. There are new rules by the Centers for Medicare & Medicaid Services for Medicare Advantage plans and Medicare and Medicaid insurance plans, requirements for qualified health care plans participating in the federally facilitated Marketplace and provider directory requirements in 26 states.

In the May 2016 Record, we informed you that Atlas Systems will help gather information for our provider directory.

Working with CAQH
Within in the next couple of months, Blue Cross and BCN will work with CAQH**, a nonprofit alliance, to ensure that the information in our provider directory is accurate and up to date. Our goal is to help you avoid frequent outreach for the same information by multiple health care plans, which could create a significant burden on your staff’s time and resources.

For many years, we’ve been a participant in CAQH ProView, which streamlined the credentialing process. Now we’re working together to use that same information to simplify the process of updating provider directories. We’ll be using CAQH ProView for our quarterly directory attestation.

Blue Cross and BCN worked with CAQH to begin a multi-plan initiative to encourage physicians and other health care professionals with existing CAQH ProView®** profiles to:

  • Review their current information in a new “Provider Directory Snapshot” as part of their regular re-attestation process
  • Make updates to their information and affiliations, as appropriate
  • Re-attest that this information is current, accurate and complete and may be published in the provider directories for the participating health care plans that they designate

After Blue Cross and BCN receive this information, we’ll incorporate it into our provider files. To meet CMS and other requirements, CAQH will reach out to you once each quarter to review and update your directory information. We also encourage other health care plans you contract with to participate in this initiative as well.

If you have questions about your provider file information or about CAQH ProView**, contact your provider consultant. To learn more about the CAQH Provider Directory initiative**, go to caqh.org**.

**Blue Cross Blue Shield of Michigan doesn't own or control the content of this website.


Here’s what you need to know about surgical debridement and routine foot care coding

Debridement is the surgical removal of infected, weakened or pathological tissue, as well as foreign material. Postoperative complications, such as a deep wound gap or wound infection, may require surgical debridement.

The patient’s medical records must document both the need for and performance of these services. You can use the following procedure codes to report the appropriate description and level of wound debridement:

*11000
*11001
*11042
*11043
*11044
*97597

Note: Codes *11040 and *11041 have been discontinued.

Don't use the codes above when reporting:

  • Postoperative debridement of incisions, which involve normal exfoliation of the superficial layers of the skin
  • Procedures using chemical, cryotherapy, laser or other destruction where there's expected exfoliation or drainage secondary to the procedure performed

Routine foot care guidelines

Debridement for routine foot growths — corns, calluses — refers to the paring, curettement, shaving, cutting or sharp dissection of nonpathological tissue, which isn't associated with a wound, ulceration or infected tissue.
Routine foot care is the routine treatment and cutting of corns, calluses and nail treatment. It includes paring, cutting, debridement and curettement of:

  • Corns
  • Calluses
  • Nails
  • Benign lesions or other thickened skin
  • Toenails infected with a fungus

Blue Cross Blue Shield of Michigan doesn't cover routine foot care, except for the following groups:

  • Kmart
  • Michigan Education Special Services Association, or MESSA
  • State of Michigan

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


Documenting and coding arthrocentesis procedures

Taber’s Cyclopedic Medical Dictionary defines arthrocentesis as “Puncture of a joint space by using a needle; usually done in order to remove accumulated fluid from the joint.”

Arthrocentesis is a widely used and relatively uncomplicated procedure to perform. It's an effective diagnostic and therapeutic method that introduces a corticosteroid or a local anesthetic agent into a joint when medically necessary and appropriate.

Complications, side effects and contraindications for this procedure may include:

  • Exacerbation of infection
  • Damage to joint tissues
  • Tendon rupture
  • Ligament rupture
  • Masking of advancing disease activity
  • Septic arthritis
  • Neuropathic arthropathy
  • Muscle atrophy
  • Local osteoporosis
  • Avascular necrosis
  • Fatty atrophy
  • Delayed healing

Documentation requirements
Medical records must chronologically document the patient’s medical history and physical exam in sufficient detail to ensure that he or she receives high-quality care. This will also allow a fair and accurate review of a physician’s services by payers.

The patient's chart should include:

  • Symptoms and physical findings
  • Diagnosis
  • Specific procedure performed
  • Exact site of injection
  • Amount and dose of the anesthetic agent or the anti-inflammatory agent used in the injection
  • Physician’s rationale for each injection and treatment plan
  • Patient’s condition and response to the procedures

Also, be sure to document the following in the patient's chart:

  • Clearly stated and specific rationale for extending treatment beyond three to five injections for one joint or area
  • Patient response to previous treatments
  • A proposed plan for the resolution of the problem
  • A proposal for alternative therapy if there's inadequate patient response

Coding guidelines
Intra-articular steroid injections are included as part of arthrocentesis surgical procedures. There's no separate reimbursement for the medication.

Code*

Explanation

Guidelines

20600

Arthrocentesis, aspiration or injection; small joint, bursa or ganglion cyst (for example, fingers or toes)

For injections of the fingers or toes, up to and including metacarpophalangeal and metatarsophalangeal joints

20605

Arthrocentesis, aspiration or injection; intermediate joint, bursa or ganglion cyst (for example, temporomandibular, acromioclavicular, wrist, elbow or ankle or olecranon bursa)

For injection of the joints or bursae nearby the fingers, up to and including the wrist and elbow joints. Could include the carpal-metacarpal and wrist joints, elbow and olecranon bursae. In the foot, it would include the tarsal-metatarsal, intertarsal and ankle joints.

20610

Arthrocentesis, aspiration or injection; major joint or bursa (for example, shoulder, hip, knee joint or subacromial bursa)

For injections of the major joints or bursae of the body, including the shoulder, hip, knee joint and subacromial bursa.


Beacon Health offers behavioral health consultation services to physicians regarding URMBT members

Beacon Health offers Blue Cross Blue Shield of Michigan participating primary care physicians the opportunity to consult with a psychiatrist regarding patients who are members of the UAW Retiree Medical Benefits Trust.

Beacon Health is the behavioral health manager for the URMBT.

Physicians can schedule a telephone consultation with a board-certified psychiatrist to discuss behavioral health conditions typically seen in a primary care setting, such as depression, anxiety, bipolar disorder and substance abuse. They can seek advice on the diagnosis, treatment and medication for these conditions.

Call the Beacon Health PCP hotline at 1-877-241-5575 to schedule a consultation Monday through Friday from 7 a.m. to 3:30 p.m. Eastern time. There is no cost for this service for either the physician or the patient.

Did you know? Appropriate and early treatment of behavioral health issues can improve a patient’s overall medical care and reduce medical complications down the road.


Reminder: Blue Cross expanding 24/7 online health care coverage

On July 1, Blue Cross Blue Shield of Michigan will expand 24/7 online health care services with American Well® to all underwritten Blue Cross groups and individuals.

Blue Cross has contracted with American Well, an independent company, to provide online health care for our members.

As you read in The Record previously, this service has been available since Jan. 1, 2016, to Blue Cross and Blue Care Network self-funded groups that choose to participate, as well as to all BCN underwritten groups and individuals.

Physicians who already provide — or who wish to provide — their own telemedicine services should review Blue Cross’ updated telemedicine policy in the billing chart in the February Record. The policy, effective Jan. 1, 2016, is detailed in the “Updates to payable procedures” section of the chart.

To review BCN’s telemedicine policy, see the March – April issue of BCN Provider News.

If you choose not to provide telemedicine services, your patients may have covered services through our arrangement with American Well.


Reminder: Reporting insertion and removal of bone fixation devices

Insertion of fixation devices
Use procedure code *20650 for skeletal traction or for the percutaneous fixation of a fracture or dislocation. Bill either closed reduction or percutaneous fixation — not both.

Code

Explanation

*20650

Insertion of wire or pin with application of skeletal traction, including removal (separate procedure)

Removal of fixation devices
Reimbursement for removing the external bone fixation devices is included in the reimbursement for the original surgical procedure in which the devices were inserted. Procedures would not be billed separately from the initial surgical procedure.

However, you may bill procedure code *20670 as a separate code if you’re not an associate of or a member of the same group as the original operating physician.

Code

Explanation

*20670

Removal of implant; superficial, (buried wire, pin or rod)

Superficial pin removal refers to K-wires, or to buried wire or rods within the skin layer that may be removed with or without local anesthesia, but don't require incision or dissection of muscle, tendon or fascia. Pins located distal to the metacarpal or metatarsal joints are all considered superficial pin removal whether or not the pins are located below the dermis.

Code

Explanation

*20680

Removal of implant; deep (e.g., buried wire, pin, screw, metal band, nail, rod or plate)

Deep pin removal refers to removal of a wire, pin, screw, metal band, nail, rod or plate that’s buried so that the ends or surface are located beneath the dermal layer.

Note: Do not use procedure code *20680 to report the removal of temporary K-wires.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


Clarification: Coverage for physical therapy procedure codes when supervised by a chiropractor

In the August 2015 Record, we published an article announcing that additional physical therapy procedure codes are payable to chiropractors. The article also should have stated that for Michigan Education Special Services Association members, additional physical therapy procedure codes are payable when supervised by a chiropractor.

This means that chiropractors can delegate physical medicine services, including massage therapy, to another person. The chiropractor isn't required to provide them directly.

A member doesn’t need a prescription to receive covered physical medicine services from a chiropractor. But for these services to be reimbursed, the chiropractor must develop a physical medicine treatment plan after the member’s first physical medicine service.

The only exception to this requirement is for mechanical traction (procedure code *97012), which may be performed at subsequent visits without a physical medicine treatment plan. Blue Cross Blue Shield of Michigan maintains the current payment structure for these treatments.

Keep in mind that no physician agreement or signature is required on a treatment plan for MESSA members.

Check the billing chart under Updates to Payable Procedures in the August 2015 Record for a list of procedure codes that were newly reimbursable to chiropractors.


Reminder: When billing chiropractic claims, include all required documentation

When chiropractors bill for procedure code *97012 and other physical therapy codes, they must include the following information in their documentation:

  • The device used to apply the therapy
  • The anatomic location of the therapy (for example, cervical, thoracic or lumbar region of the spine)
  • The time of treatment
  • The medical justification (for example, to reduce a disc bulge or reduce scarring)

This information is required for reimbursement. Also, remember that you're subject to all Blue Cross Blue Shield of Michigan documentation guidelines located on the following sites:

  • Our online Chiropractor provider manual on web-DENIS
  • The Record newsletter articles
  • Web-DENIS broadcast messages
  • The ChiroCode DeskBook for chiropractic coding, reimbursement and compliance

To locate our online Chiropractor provider manual and find billing guidelines, log in to web-DENIS and follow these steps:

  • Click on BCBSM Provider Publication and Resources.
  • Click on Provider Manual.
  • Enter the provider type and click on Search.
  • Click on Chiropractic Services.
  • Click on Billing Guidelines.

Pharmacy

Blue Cross not covering select high-cost drugs with comparable alternatives

To address the high cost of drugs and provide the best value for our members, Blue Cross Blue Shield of Michigan commercial plans will no longer cover select high-cost, U.S. Food and Drug Administration-approved drugs for which more cost-effective therapeutic alternatives are available. This doesn't apply to Michigan Education Special Services Association members.

The initial drugs targeted for this initiative are Jublia®, Kerydin® and Onmel®, a group of medications used to treat onychomycosis, or toenail fungus. These drugs will no longer be covered beginning Aug. 1, 2016.

The following table includes the approximate cost of the brand-name drugs and associated therapeutic alternatives:

Brand-name drugs not covered beginning Aug. 1, 2016, and their costs**

Therapeutic alternatives and their costs**

Jublia topical solution (eficonazole)

$1,290

ciclopirox topical solution (Penlac®)

$50

Kerydin topical solution (tavaborole)

$1,614

terbinafine tablet (Lamisil®)

$390

Onmel tablet (itraconazole)

$1,164

itraconazole capsule (Sporanox®)

$557


**Approximate cost for a 30-day supply based on the average wholesale price.

In some cases, members’ out-of-pocket costs for these brand-name drugs may be lower than their copay due to manufacturer savings cards. However, the high cost of these drugs is reflected in future premium rates and may affect the claims experience for both members and plans.

As part of this ongoing initiative, Blue Cross will continue to identify select high-cost drugs and will stop covering them when there are more cost-effective alternatives available for our commercial members.


Blue Cross adding 2 additional specialty drugs to Medical Drug Prior Authorization program Oct. 1

Beginning Oct. 1, 2016, two more specialty drugs will need prior authorization from Blue Cross Blue Shield of Michigan before they’ll be covered under a member's medical benefits.

Keep in mind that prior authorization is just a clinical review approval, not a guarantee of payment. Providers will still need to verify the necessary coverage for this medical benefit. Our office will accept the medical drug prior authorization request forms, with supporting documentation, for these newly added drugs as early as Aug. 1, 2016.

Starting Oct. 1, 2016, the following two drugs will need prior authorization:

Drug name

HCPCS code

Inflectra

Q5102

Remicade®

J1745

You can find medication request forms, within the list of medications that need prior authorization, on web-DENIS:

  1. Click on BCBSM Provider Publications and Resources.
  2. Click on Commercial Pharmacy Prior Authorization and Step Therapy forms.
  3. Click on Physician administered medications (on the right side under Frequently Used Forms).

We won’t consider a request for coverage until we receive a physician-signed medication request form faxed or mailed to Blue Cross, or a request uploaded onto NovoLogix, an online-based tool. Standard processing time for request review is 15 days. An urgent request can be reviewed within 72 hours.

The list** below shows all the medications that are part of the Medical Drug Prior Authorization Program.

Actemra®

Depo®-Testosterone

Immune globulin

Prolia®

Acthar® gel

Dysport®

Kalbitor®

Ruconest®

Adagen®

Elaprase®

Kanuma™

Signifor® LAR

Aldurazyme®

Elelyso™

Krystexxa®

Simponi® Aria™

Aralast NP™

Entyvio™

Lemtrada™

Soliris®

Aveed®

Fabrazyme®

Lumizyme®

Stelara®

Benlysta®

Firazyr®

Makena®

Synagis®

Berinert®

Flebogamma® DIF

Myobloc®

Testopel®

Bivigam™

Gammagard Liquid®

Myozyme®

Tysabri®

Botox®

Gammagard® S/D

Naglazyme®

Vimizim™

Carimune® NF

Gammaked®

Nplate®

Vpriv®

Cerezyme®

Gammaplex®

Nucala®

Xeomin®

Cimzia®

Gamunex®

Octagam®

Xgeva®

Cinqair®

Glassia™

Orencia®

Xiaflex®

Cinryze®

Hizentra®

Privigen®

Xolair®

Cosentyx™

HyQvia®

Probuphine®

Zemaira®

Delatestryl®

Ilaris®

Prolastin®-C

 

Note: The prior authorization requirement doesn’t apply to Medicare, Medicare Advantage or Federal Employee Program® members.

**Blue Cross reserves the right to change this list at any time.


Facility

Here’s how newborn coverage was updated

When Blue Cross Blue Shield of Michigan became a mutual company in January 2014, its newborn coverage policy changed. We want to make sure you are aware of these updates.

Newborn coverage changes

  • Newborns are covered for the first 31 days from the date of their birth whether or not the baby is listed on the subscriber’s contract. Coverage includes both well-baby care visits and claims for injury, sickness, congenital defects and birth abnormalities. If the baby is not enrolled on the subscriber’s contract on day 32, coverage under our 31-day newborn coverage policy terminates.
  • The 31-day newborn coverage policy applies to either the mother’s or the father’s contract, whoever is the subscriber. The mother is not required to be listed on the father’s contract for the newborn to be covered.
  • The 31-day newborn coverage does not apply to the newly born child of a dependent. If the mother is a dependent (not the subscriber or the spouse) on the contract, then claims for the newborn will be denied. Blue Cross does not provide coverage to the newborn of a dependent unless the subscriber has legal responsibility for the newborn. Coverage for the newborn may be available through other sources.

Note: The 31-day newborn coverage policy does not apply to Federal Employee Program® members. For self-funded groups, newborn coverage is determined by the group’s plan.

For additional information about our newborn coverage policy, refer to the benefit section of our online provider manuals, which will be updated to include information on this policy July 1, 2016.

If you have questions regarding a denied claim or to status a claim that you reported, please contact Provider Inquiry.


Reminder: Follow billing guidelines when purchasing, administering medical drugs to outpatients

When a hospital purchases and administers a medical drug for a Blue Cross Blue Shield of Michigan member who is an outpatient, the hospital should bill the revenue code and corresponding procedure code for both the drug and its administration, using separate revenue lines.

See the example below:

1

When a hospital administers a drug in an outpatient setting that isn’t purchased by the hospital, the hospital should bill for the administration. However, the hospital should include the revenue code and corresponding procedure code for the medical drug with total charges of $.01.

See the example below:

2


DME

System updated to process DME/P&O and medical supply claims with office location

Blue Cross and Blue Shield of Michigan’s claims processing system has been updated to process all durable medical equipment, prosthetic, orthotics and medical supply claims with an office location.


Reminder: Procedure code E0485 not covered beginning Aug. 1

In alignment with Medicare’s policy, we’ll no longer pay for procedure code E0485 beginning Aug. 1, 2016. The code relates to a seldom-prescribed, pre-fabricated oral appliance.

We’ve been posting messages on web-DENIS about this coverage change since April.

Note: Federal Employee Program® and Michigan Public School Employees Retirement System members are excluded from this change.

A custom oral appliance may still be covered. We’ll provide more details in The Record in the near future.


Medicare Advantage

New webinar series on Prospective Provider Engagement Program now available

Blue Cross Blue Shield of Michigan and Blue Care Network have teamed with Data Driven Delivery Systems to provide an updated webinar on the Prospective Provider Engagement Program. The program is targeted to health care providers who treat Medicare Advantage patients.

This five-part educational program includes:

  • A refresher course on how to accurately document patient conditions in a manner that’s compliant with the Centers for Medicare & Medicaid Services
  • Program overview
  • Clinical scenarios highlighting real-world examples to improve documentation accuracy
  • Clinical expertise and support from Osamah El-Aroud, M.D., DDS medical director for Michigan

You can click on the links below to access the following modules:

  1. Introduction to Risk Adjustment
  2. DDS Program Overview
  3. DDDS Clinical Documentation
  4. Documentation Improvement Scenario — Diabetes with Complications, Morbid Obesity and Major Depression
  5. Documentation Improvement Scenario — Angina, Pulmonary Hypertension and Secondary Hyperparathyroidism.

Each module lasts about 15 minutes. You can fast-forward, rewind or pause the recordings at any time and view as many times as you like.

How to print the presentation

You can print the presentation by clicking on the question mark icon in the lower right-hand corner of the viewing window. Select the Print Slides option.

About the presenter

Dr. El-Aroud has extensive experience in risk adjustment, Medicare Risk Adjustment Factor scores and Hierarchical Condition Category coding as they apply to the clinical world. He was instrumental in developing and implementing the Prospective Provider Engagement Program.

FAQs

You can access some of the most frequently asked questions by physicians by clicking on the attachments tab in the left-hand navigation menu and downloading the FAQs attachment.


Medicare Plus BlueSM PPO prior authorization program to continue its expansion

Blue Cross Blue Shield of Michigan will expand its prior authorization program later this year to include three additional types of services for our Medicare Plus BlueSM PPO members who reside in Michigan and use Michigan providers.

The expansion is intended to eliminate the unnecessary use of certain procedures to improve patient care and manage health care costs. Following are the three additional types of services that will require prior authorization:

  • Lumbar spinal fusion surgery — Manage the utilization of spinal fusion surgeries to ensure clinical appropriateness.
  • Interventional pain management — Manage the use of interventional pain procedures, including epidural injections, facet block and radiofrequency ablations, to help eliminate inappropriate delivery of such procedures.
  • Radiation oncology — Manage the use of radiation therapy inclusive of modalities, dosing, coding and treatment goals, while reducing expenditures and the patient’s exposure to radiation therapy.

Prior authorization for these services will be administered by eviCore healthcare. EviCore is a national specialty benefit management company that focuses on managing quality and use for individual patients.

Providers will need to contact eviCore to request prior authorization for these services. If a prior authorization isn’t obtained for the above-mentioned services, claims will be denied as provider-liable.

For more information on changes to the post-acute care prior authorization process, read Reminder: Medicare Plus BlueSM post-acute care prior authorization process changing June 1 in the June Record.

We’ll provide more details about these changes in future issues of The Record. We’ll also announce opportunities for training on the prior authorization expansion through web-DENIS broadcast messages.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2015 American Medical Association. All rights reserved.